Tuğba YANIK YALÇIN, Çiğdem EROL, Saliha AYDIN, Nuran SARI, Özlem KURT AZAP, Hande ARSLAN

İnfluenza Hızlı Tanı Testi Sonuçları Gerçeği Yansıtıyor mu?

Amaç: Grip, mevsimsel salgınlara ve dünya çapında çok sayıda pandemiye yol açar. Bu nedenle hızlı teşhis ve tedavisi önemlidir. Bu çalışmada influenza hızlı tanı testleri (RIDT) sonuçları ile klinik arasındaki korelasyon değerlendirildi. Gereç ve Yöntem: 2018-2019 influenza sezonunda hastanemizde RIDT yapılan toplam 795 hasta çalışmaya dahil edildi. Test sonuçlarına göre hastalar iki gruba ayrıldı. Tanı testi sonucu pozitif olan hastalar influenza pozitif (Flu+) gruba, tanı testi sonucu negatif olan hastalar influenza negatif (Flu-) gruba dahil edildi. Bulgular: RIDT’si pozitif olan 248 hastanın verileri, tanı testi sonucu negatif olan 547 hastanın verileri ile karşılaştırıldı. Ateş, Flu+ grupta 199 (%80,2), Flu- grupta 209 (%38,2) hastada mevcuttu (p

Do the Rapid Influenza Diagnostic Tests Results Reflect the Truth?

Objectives: Influenza (flu) causes seasonal epidemics and has led to numerous pandemics worldwide. Its rapid diagnosis and treatment are critical. This study evaluated the correlation between rapid influenza diagnostic test (RIDT) results and clinical reflection. Materials and Methods: A total of 795 patients who were performed the RIDT during the 2018-2019 influenza season were included. According to the test results, the patients were then divided into two groups. The Flu+ group was composed of patients with positive diagnostic test results, while the Flu- group was those with negative test results. Results: The data of 795 patients with 248 positive RIDTs were compared with the data of 547 patients with negative test results. Fever was present in 199 (80.2%) patients in the Flu+ group and in 209 (38.2%) patients in the Flu- group (p

PDF

___

1. Weekly Influenza (Flu) Surveillance Report..Accessed November 28, 2020. https://grip.gov.tr/depo/influenza-raporu/2018/InfluenzaGrip_Surveyans_ Raporu_2019_21-39._hafta.pdf.
2. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019;68:e1-e47.
3. Guidance for Clinicians on the Use of Rapid Influenza Diagnostic Tests. Accessed November 28, 2020. https://www.cdc.gov/flu/pdf/professionals/ diagnosis/clinician_guidance_ridt.pdf.
4. Wong PL, Sii HL, P’ng CK, et al. The effects of age on clinical characteristics, hospitalization and mortality of patients with influenza-related illness at a tertiary care centre in Malaysia. Influenza Other Respir Viruses. 2020;14:286-293.
5. Casalegno JS, Eibach D, Valette M, et al. Performance of influenza case definitions for influenza community surveillance: based on the French influenza surveillance network GROG, 2009-2014. Euro Surveill. 2017;22:30504.
6. Shah SC, Rumoro DP, Hallock MM, et al. Clinical predictors for laboratoryconfirmed influenza infections: exploring case definitions for influenzalike illness. Infect Control Hosp Epidemiol. 2015;36:241-248.
7. Anderson KB, Simasathien S, Watanaveeradej V, et al. Clinical and laboratory predictors of influenza infection among individuals with influenza-like illness presenting to an urban Thai hospital over a five-year period. PLoS One. 2018;13:e0193050.
8. Monamele CG, Kengne-Nde C, Munshili Njifon HL, et al. Clinical signs predictive of influenza virus infection in Cameroon. PLoS One. 2020;15:e0236267.
9. Matsuno O, Kataoka H, Takenaka R, et al. Influence of age on symptoms and laboratory findings at presentation in patients with influenza-associated pneumonia. Arch Gerontol Geriatr. 2009;49:322-325.
10. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med. 1997;157:1453-1459.
11. Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States - 2019-2020 Influenza Season. Accessed November 26, 2020. https://www.cdc.gov/flu/about/burden/2019-2020.html.
12. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463-474.
13. Ingram PR, Inglis T, Moxon D, et al. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med. 2010;36:528- 532.
14. Cuquemelle E, Soulis F, Villers D, et al. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med. 2011;37:796-800.
15. Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care. 2014;18:R44.
16. Rodríguez AH, Avilés-Jurado FX, Díaz E, et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. J Infect. 2016;72:143-151.
17. Han Q, Wen X, Wang L, et al. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. J Clin Lab Anal. 2020;34:e23191.